Comparative Pharmacology
Head-to-head clinical analysis: LUMENHANCE versus MULTIHANCE MULTIPACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMENHANCE versus MULTIHANCE MULTIPACK.
LUMENHANCE vs MULTIHANCE MULTIPACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMENHANCE is a contrast agent that increases signal intensity in magnetic resonance imaging by shortening T1 relaxation time, enhancing tissue visualization.
Gadobenate dimeglumine is a paramagnetic contrast agent that enhances magnetic resonance imaging by increasing the relaxation rate of water protons in tissues where it accumulates. The gadolinium ion (Gd3+) shortens T1 and T2 relaxation times, leading to increased signal intensity on T1-weighted images.
1 mg intravenously once daily
0.1 mmol/kg body weight (0.2 mL/kg) intravenous bolus injection; maximum single dose 0.3 mmol/kg (0.6 mL/kg)
None Documented
None Documented
Terminal elimination half-life is 8–10 hours in healthy adults; half-life may increase up to 15 hours in moderate hepatic impairment, requiring dose adjustment.
Terminal elimination half-life: 1.5–2.2 hours in patients with normal renal function; prolonged (up to 30 hours) in severe renal impairment (eGFR <30 mL/min/1.73m²)
LUMENHANCE is primarily eliminated via renal excretion (70% unchanged) and biliary/fecal excretion (25% as metabolites). Approximately 5% is eliminated via other routes.
Renal excretion: 95% unchanged drug via glomerular filtration; biliary/fecal: <0.1%
Category C
Category C
MRI Contrast Agent
MRI Contrast Agent